# Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients

> **NCT00548769** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 37 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Formulation A
- **DRUG:** Formulation B
- **DRUG:** Formulation C
- **DRUG:** Formulation D

## Key facts

- **NCT ID:** NCT00548769
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-21
- **Primary completion:** 2007-11-26
- **Final completion:** 2007-11-26
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2017-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00548769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00548769, "Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00548769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*